ATE485303T1 - Isoformen von gehirn-natriuretischem peptid - Google Patents

Isoformen von gehirn-natriuretischem peptid

Info

Publication number
ATE485303T1
ATE485303T1 AT04754213T AT04754213T ATE485303T1 AT E485303 T1 ATE485303 T1 AT E485303T1 AT 04754213 T AT04754213 T AT 04754213T AT 04754213 T AT04754213 T AT 04754213T AT E485303 T1 ATE485303 T1 AT E485303T1
Authority
AT
Austria
Prior art keywords
isoforms
natriuretic peptide
brain natriuretic
conditions
kidney
Prior art date
Application number
AT04754213T
Other languages
English (en)
Inventor
Shuchong Pan
Robert Simari
Original Assignee
Mayo Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mayo Foundation filed Critical Mayo Foundation
Application granted granted Critical
Publication of ATE485303T1 publication Critical patent/ATE485303T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Brain natriuretic peptide [BNP, proBNP]; Cardionatrin; Cardiodilatin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/325—Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Peptides Or Proteins (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT04754213T 2003-06-20 2004-06-02 Isoformen von gehirn-natriuretischem peptid ATE485303T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48046003P 2003-06-20 2003-06-20
PCT/US2004/017554 WO2005000095A2 (en) 2003-06-20 2004-06-02 Isoforms of brain natriuretic peptide

Publications (1)

Publication Number Publication Date
ATE485303T1 true ATE485303T1 (de) 2010-11-15

Family

ID=33551922

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04754213T ATE485303T1 (de) 2003-06-20 2004-06-02 Isoformen von gehirn-natriuretischem peptid

Country Status (12)

Country Link
US (2) US8354496B2 (de)
EP (2) EP1638443B1 (de)
JP (1) JP4881156B2 (de)
CN (1) CN101208353B (de)
AT (1) ATE485303T1 (de)
DE (1) DE602004029680D1 (de)
DK (1) DK1638443T3 (de)
ES (1) ES2354881T3 (de)
IL (1) IL172674A (de)
PL (1) PL1638443T3 (de)
PT (1) PT1638443E (de)
WO (1) WO2005000095A2 (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602004029680D1 (de) 2003-06-20 2010-12-02 Mayo Foundation Isoformen von gehirn-natriuretischem peptid
EP1698058A4 (de) * 2003-12-18 2009-09-23 Inverness Medical Switzerland Überwachungsverfahren und -vorrichtung
GB0329288D0 (en) 2003-12-18 2004-01-21 Inverness Medical Switzerland Monitoring method and apparatus
PL2348114T3 (pl) 2004-04-21 2019-08-30 Alexion Pharmaceuticals, Inc. Koniugaty do dostarczania do kości i sposób ich wykorzystania do nakierowywania białek na kość
US20070042957A1 (en) * 2005-08-19 2007-02-22 Mayo Foundation For Medical Education And Research Type v phosphodiesterase inhibitors and natriuretic polypeptides
KR100702415B1 (ko) * 2006-03-03 2007-04-09 안웅식 올리고 핵산 탐침 비드 어레이를 이용한 인유두종바이러스검출 키트 및 방법
KR100736442B1 (ko) * 2006-03-10 2007-07-09 주식회사 나노텍세라믹스 라텍스 바인딩된 저비산 실리카 조성물과 이의 제조방법
WO2008021872A1 (en) * 2006-08-08 2008-02-21 Mayo Foundation For Medical Education And Research Diuretic and natriuretic polypeptides
EP2295445A1 (de) 2006-09-08 2011-03-16 Mayo Foundation for Medical Education and Research Aquaretische und natriuretische Polypeptide ohne Gefäßerweiterungsaktivität
WO2009036448A2 (en) * 2007-09-15 2009-03-19 Mayo Foundation For Medical Education And Research Natriuretic peptide receptor-c agonists
WO2010029116A1 (en) * 2008-09-11 2010-03-18 F. Hoffmann-La Roche Ag Natriuretic peptides and adiponectin in subjects with a metabolic syndrome
JP4834190B2 (ja) 2009-07-23 2011-12-14 株式会社 イギス 皮膚外用剤組成物
NZ598600A (en) 2009-08-27 2014-03-28 Kyoko Endo Therapeutic agent for rhinitis
AU2011350066A1 (en) 2010-12-27 2013-07-11 Alexion Pharma International Sarl Compositions comprising natriuretic peptides and methods of use thereof
CN102174636B (zh) * 2011-01-11 2013-10-30 中国食品药品检定研究院 应用gca稳定转染细胞系测定bnp活性
CN110801514A (zh) 2011-01-21 2020-02-18 Igisu株式会社 秃头症治疗剂
WO2013032784A1 (en) 2011-08-30 2013-03-07 Mayo Foundation For Medical Education And Research Natriuretic polypeptides
WO2013070741A1 (en) * 2011-11-11 2013-05-16 Mayo Foundation For Medical Education And Research Methods and materials for regulating natriuretic polypeptide function
US9611305B2 (en) 2012-01-06 2017-04-04 Mayo Foundation For Medical Education And Research Treating cardiovascular or renal diseases
US10052366B2 (en) 2012-05-21 2018-08-21 Alexion Pharmaceuticsl, Inc. Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
JP6532460B2 (ja) * 2013-07-26 2019-06-19 コーニンクレッカ フィリップス エヌ ヴェＫｏｎｉｎｋｌｉｊｋｅ Ｐｈｉｌｉｐｓ Ｎ．Ｖ． 患者モニタリングシステムに関する臨床規則及び規定のコンピュータ化及び視覚化
WO2016007873A1 (en) 2014-07-11 2016-01-14 The Regents Of The University Of Michigan Compositions and methods for treating craniosynostosis
CN107405390A (zh) 2014-12-05 2017-11-28 阿雷克森制药公司 用重组碱性磷酸酶治疗癫痫
CA2973883A1 (en) 2015-01-28 2016-08-04 Alexion Pharmaceuticals, Inc. Methods of treating a subject with an alkaline phosphatase deficiency
WO2017031114A1 (en) 2015-08-17 2017-02-23 Alexion Pharmaceuticals, Inc. Manufacturing of alkaline phosphatases
EP3355904A4 (de) 2015-09-28 2019-06-12 Alexion Pharmaceuticals, Inc. Identifizierung wirksamer dosierungsschemata für gewebeunspezifische alkalische phosphatase-enzymersatztherapie von hypophosphatasie
WO2017074466A1 (en) 2015-10-30 2017-05-04 Alexion Pharmaceuticals, Inc. Methods for treating craniosynostosis in a patient
US11065306B2 (en) 2016-03-08 2021-07-20 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in children
WO2017173395A1 (en) 2016-04-01 2017-10-05 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in adolescents and adults
EP3436052A4 (de) 2016-04-01 2019-10-09 Alexion Pharmaceuticals, Inc. Behandlung von muskelschwäche mit alkalischen phosphatasen
EP3464573A4 (de) 2016-06-06 2020-02-19 Alexion Pharmaceuticals, Inc. Auswirkungen von metallen auf die herstellung von alkalischen phosphatasen
WO2018035420A1 (en) 2016-08-18 2018-02-22 Alexion Pharmaceuticals, Inc. Methods for treating tracheobronchomalacia
BR112019020506A2 (pt) 2017-03-31 2020-08-04 Alexion Pharmaceuticals, Inc. métodos para o tratamento de hipofosfatasia (hpp) em adultos e adolescentes
EP3773684A1 (de) 2018-03-30 2021-02-17 Alexion Pharmaceuticals, Inc. Herstellung von glycoproteinen
BR112023016048A2 (pt) 2021-02-12 2023-11-14 Alexion Pharma Inc Polipeptídeos de fosfatase alcalina e métodos de uso dos mesmos
TW202419463A (zh) 2022-11-02 2024-05-16 丹麥商諾佛 儂迪克股份有限公司 Cnp化合物

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4233402A (en) 1978-04-05 1980-11-11 Syva Company Reagents and method employing channeling
WO1984003285A1 (en) 1983-02-22 1984-08-30 Molecular Biosystems Inc Defined sequence single strand oligonucleotides incorporating reporter groups, process for the chemical synthesis thereof, and nucleosides useful in such synthesis
US4506671A (en) 1983-03-30 1985-03-26 United States Surgical Corporation Apparatus for applying two-part surgical fasteners
US4496544A (en) 1983-11-10 1985-01-29 Washington University Atrial Peptides
US5212286A (en) 1984-04-19 1993-05-18 Scios Nova Inc. Atrial natriuretic/vasodilator peptide compounds
US4996143A (en) 1985-12-23 1991-02-26 Syngene, Inc. Fluorescent stokes shift probes for polynucleotide hybridization
US5114923A (en) 1988-05-31 1992-05-19 California Biotechnology Inc. Recombinant techniques for production of novel natriuretic and vasodilator peptides
CA1339210C (en) * 1988-05-31 1997-08-05 John Lewicki Recombinant techniques for production of novel natriuretic and vasodilator peptides
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
JP2809533B2 (ja) * 1991-01-31 1998-10-08 壽之 松尾 Ｃｎｐ類似体ペプチド
US5296347A (en) 1991-02-08 1994-03-22 Ciba Corning Diagnostics Corp. Bridge immunoassay
EP1067134B1 (de) 1991-11-07 2004-07-28 Nanotronics, Inc. Hybridisierung von mit Chromophoren und Fluorophoren konjugierten Polynukleotiden zur Erzeugung eines Donor-Donor Energietransfersystems
WO1994020534A1 (en) * 1993-03-03 1994-09-15 Mayo Foundation For Medical Education And Research Vasonatrin peptide and analogs thereof
US5846932A (en) 1993-11-12 1998-12-08 Genentech, Inc. Receptor specific atrial natriuretic peptides
US5665704A (en) * 1993-11-12 1997-09-09 Genentech, Inc. Receptor specific atrial natriuretic peptides
WO1995024419A1 (en) * 1994-03-11 1995-09-14 Ariad Pharmaceuticals, Inc. Methods and materials for identifying inhibitors of molecular interactions mediated by sh3 domains
EP2292662B1 (de) 1996-03-04 2014-04-23 Scios Inc. Testverfahren und Reagenzien zur Quantifizierung von hBNP
US6828107B2 (en) * 1997-09-11 2004-12-07 Shionogi & Co., Ltd. Immunoassay method for BNP
US6551795B1 (en) 1998-02-18 2003-04-22 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to pseudomonas aeruginosa for diagnostics and therapeutics
US6887481B1 (en) * 1998-12-16 2005-05-03 Agency For Science, Technology And Research Bacterial-derived molecules and therapeutic and diagnostic uses therefor
US6887470B1 (en) 1999-09-10 2005-05-03 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
US6849714B1 (en) 1999-05-17 2005-02-01 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
WO2000071576A2 (en) 1999-05-24 2000-11-30 Mayo Foundation For Medical Education And Research Adenovirus vectors encoding brain natriuretic peptide
US6407211B1 (en) 1999-12-17 2002-06-18 Mayo Foundation For Medical Education And Research Chimeric natriuretic peptides
US20110131679A2 (en) * 2000-04-19 2011-06-02 Thomas La Rosa Rice Nucleic Acid Molecules and Other Molecules Associated with Plants and Uses Thereof for Plant Improvement
US6812339B1 (en) * 2000-09-08 2004-11-02 Applera Corporation Polymorphisms in known genes associated with human disease, methods of detection and uses thereof
AU2002224331A1 (en) * 2000-09-22 2002-04-02 Incyte Genomics, Inc. Transcription factors and zinc finger proteins
US7214786B2 (en) * 2000-12-14 2007-05-08 Kovalic David K Nucleic acid molecules and other molecules associated with plants and uses thereof for plant improvement
DE602004029680D1 (de) 2003-06-20 2010-12-02 Mayo Foundation Isoformen von gehirn-natriuretischem peptid
US7332569B2 (en) 2004-01-27 2008-02-19 Compugen Ltd. Brain natriuretic peptide spliced variant
EP1730181A2 (de) 2004-01-27 2006-12-13 Compugen USA, Inc. Neue natriuretische peptidvarianten im gehirn und anwendungsverfahren
WO2008021872A1 (en) 2006-08-08 2008-02-21 Mayo Foundation For Medical Education And Research Diuretic and natriuretic polypeptides
WO2009036448A2 (en) 2007-09-15 2009-03-19 Mayo Foundation For Medical Education And Research Natriuretic peptide receptor-c agonists

Also Published As

Publication number Publication date
CN101208353B (zh) 2011-12-14
EP1638443B1 (de) 2010-10-20
DK1638443T3 (da) 2011-02-07
CN101208353A (zh) 2008-06-25
EP2308889A1 (de) 2011-04-13
WO2005000095A3 (en) 2008-01-24
JP2007525957A (ja) 2007-09-13
US20070281887A1 (en) 2007-12-06
IL172674A (en) 2011-08-31
US8354496B2 (en) 2013-01-15
IL172674A0 (en) 2006-04-10
PL1638443T3 (pl) 2011-04-29
US20130143816A1 (en) 2013-06-06
EP1638443A4 (de) 2008-10-08
JP4881156B2 (ja) 2012-02-22
US8912137B2 (en) 2014-12-16
DE602004029680D1 (de) 2010-12-02
EP2308889B1 (de) 2018-05-23
WO2005000095A2 (en) 2005-01-06
ES2354881T3 (es) 2011-03-18
PT1638443E (pt) 2011-01-25
EP1638443A2 (de) 2006-03-29

Similar Documents

Publication Publication Date Title
ATE485303T1 (de) Isoformen von gehirn-natriuretischem peptid
DE60233955D1 (de) Spezifische bindungsmittel von human angiopoietin-2
DK1692158T3 (da) VEGF-binding og understøttede peptider til behandling af hudsygdomme
ATE516304T1 (de) Nrg-2 nukleinsäuren, polypeptide und diagnostische / therapeutische methoden
CY1111225T1 (el) Νεα πεπτιδια ως αναστολεις πρωτεασης νs3-σερινης ιου ηπατiτιδας c
DE60043165D1 (de) Globularer Aufbau vom Amyloid-beta- protein und deren Verwendungen
YU9404A (sh) Multimerna, usmerena kontrastna sredstva na bazi peptida
BR0309665A (pt) Tratamento de deficiência de alfa-galactosidase a
EA200900802A1 (ru) Способы и композиции для лечения амилоидных заболеваний
EA200600078A1 (ru) Способы и композиции для лечения амилоидных заболеваний
CY1112957T1 (el) Μη νευροτοξικοι παραγοντες, οι οποιοι ενεργοποιουν το πλασμινογονο για τη θεραπευτικη αγωγη εγκεφαλικου επεισοδιου
DE60326623D1 (de) P53-bindendes polypeptid
ATE323722T1 (de) Antimikrobiell wirkendes peptid
ATE416756T1 (de) Methoden zur verwendung von lamellaren körpern für therapeutische zwecke
ATE383874T1 (de) Perylenequinonen zur anwendung als sonosensitizer
DE69718146D1 (de) At1 rezeptor antagonist zur anregung von apoptosis
EA200600956A1 (ru) Молекулы-антагонисты цитокинов
ATE355063T1 (de) Methode zur behandlung von niereninsuffizienz
ATE334327T1 (de) Antriebsriemen
ATE328082T1 (de) Verkürztes bard1 protein und dessen diagnostische und therapeutische anwendungen
DE60321443D1 (de) Screening-verfahren für eine prophylaktische und therapeutische Substanz für eine Nierenerkrankung
ATE359088T1 (de) Verwendung von interleukin-18 zur behandlung von uv-assoziierten hautkrankheiten
SE0202608D0 (sv) New sequences
DK1332229T3 (da) Fremgangsmåde til screening af midler til at behandle overvægt
TR199902914T2 (xx) �zole sistolik hipertansiyonu tedavi y�ntemi.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1638443

Country of ref document: EP